Valuable, Cost-Effective Thyroid Cancer Diagnosis

By João L. Carapinha

January 10, 2025

In this article we highlight the importance of using cost-effective diagnostic methods for thyroid cancer diagnosis, particularly through Galectin-3 based immunohistochemistry. This approach is especially crucial for low- and middle-income countries, where financial constraints can limit access to advanced diagnostic solutions.

Global Pandemic of Thyroid Nodules

Thyroid nodules (TNs) are highly prevalent, affecting approximately one in four people globally, and their management poses a significant financial burden on healthcare systems, especially in low- and middle-income countries (LMICs).

Diagnostic Challenges

The primary challenge is identifying the rare malignant nodules among the multitude of benign ones to avoid unnecessary surgery. Cytologically indeterminate thyroid nodules (Bethesda categories III and IV) are particularly problematic.

Advanced Molecular Tests

Advanced molecular tests, such as Gene Expression Classifier (GEC), BRAF mutation analysis, and mutation/fusion (M/F) panels, are accurate but expensive (costing up to $3,000 to $5,000 per test). These tests are often covered by insurance in high-income countries but are not feasible for many LMICs due to their high cost.

Galectin-3 Immunohistochemistry

Galectin-3 based immunohistochemistry (IHC) is a cost-effective and reliable method for diagnosing thyroid cancer. This test is particularly effective for indeterminate thyroid nodules and has been validated in several multicentric clinical trials. With a cost of approximately $100, it is significantly cheaper than advanced molecular tests.

Diagnostic Performance

Galectin-3 ThyroTest has a sensitivity of 83%, specificity of 85%, and an accuracy of 84%. This is comparable to, though not as high as, some advanced molecular tests. However, its low cost and ease of performance make it a viable option, especially in resource-limited settings.

Cost-Effective Thyroid Cancer Diagnosis

LMICs need cost-effective analyses and priority-setting in thyroid cancer diagnosis. Galectin-3 ThyroTest, a laboratory-developed test (LDT), is not commercially distributed but can be integrated into patient care without the need for extensive regulatory approval. This makes it more accessible and cost-effective compared to commercially marketed advanced molecular tests.

Future Perspectives

Galectin-3 ThyroTest could serve as an initial diagnostic step, with advanced molecular methods used as an adjunctive option for nodules with inconclusive results. This approach could significantly reduce the socioeconomic burden of managing suspicious thyroid nodules, particularly in LMICs.

Conclusion

Galectin-3 based immunohistochemistry is a valuable and cost-effective method for diagnosing thyroid cancer, especially in settings where advanced molecular tests are financially unfeasible. There’s a need to recognize and utilize such “good enough” methods to improve healthcare outcomes and reduce the economic burden associated with thyroid cancer management. The integration of Galectin-3 testing can pave the way for better accessibility to diagnostic resources in low-resource environments.

Reference url

Recent Posts

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

tislelizumab NSCLC treatment
        

Early Benefit Assessment of Tislelizumab NSCLC Treatment: Insights and Implications

🧐 How is the evolving treatment landscape for NSCLC affecting patient access to tislelizumab?

The German Federal Joint Committee (G-BA) has launched an early benefit assessment for tislelizumab as a second-line treatment for adults with advanced NSCLC. This assessment notably focuses on PD-L1 negative patients and highlights the need for additional data to substantiate its value amidst a shifting emphasis on first-line immunotherapy.

Explore the nuances of this assessment and its implications for future research and market access in the full article.

#SyenzaNews #oncology #MarketAccess

colorectal cancer screening
    

Advances in Colorectal Cancer Screening: Access and Cost

🚀 Is blood-based screening redefining colorectal cancer detection?

The Shield blood test offers a non-invasive alternative to colonoscopy—boosting screening uptake, but raising questions around effectiveness and value.

🔍 Discover how this innovation could reshape patient care, payer strategy, and health system costs.

#SyenzaNews #HealthcareInnovation #CostEffectiveness #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.